Srpk1 inhibitors and methods of use

A compound having a structure of Formula (I):

• wherein
• ring A is a 5-10-membered heterocycle having 1, 2, or 3 ring heteroatoms independently selected from N, O, and S;
• Cy is a 4-10-membered heterocycle having 1, 2, or 3 ring heteroatoms independently selected from N, O, and S and optionally substituted with 1 to 4 RA;
• each RA is independently halo, OH, oxo, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C0-6alkylene-N(RN)2, C0-6alkylene-C(O)N(RN)2, C0-6alkylene-OC(O)C1-6alkyl, C0-6alkylene-C(O) C1-6alkyl, C0-6alkylene-CO2RN, or C0-6alkylene-4-8-membered heterocycle having 1, 2, 3 or 3 ring heteroatoms independently selected from N, O, and S;
• R1 is H, halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, C1-6haloalkoxy, or C3-6cycloalkyl;
• R2 is halo, C1-6alkoxy, C1-6haloalkoxy, C1-6alkyl, C2-6alkene, C2-6alkyne, C1-6haloalkyl, CO2H, or Het;
• Het is a 5-8-membered heterocycle having 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, and is optionally substituted with 1 or 2 RB;
• each RB is independently halo, OH, oxo (═O), C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C0-6alkylene-N(RN)2, or C0-6alkylene-4-8-membered heterocycle having 1, 2, 3 or 3 ring heteroatoms independently selected from N, O, and S;
• R3 is H, halo, or C1-6alkyl;
• and
• each RN is independently H or C1-3alkyl, or a pharmaceutically acceptable salt thereof.